Subtype
High Grade Astrocytic Tumor
CI-CAN-00005503Explore in graph →
495 active trials2 approved drugs51 evidence items
- NCIt
- C102897
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00005503Explore in graph →
Clinical trials
1,778 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (283)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00379470 | Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM) | completed | Phase 3 | 236 | NovoCure Ltd.INDUSTRY | 7 | May 1, 2012 | clinicaltrials |
| NCT00132158 | ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors | completed | Phase 1 | 19 | St. Jude Children's Research HospitalOTHER | 1 | Apr 17, 2012 | clinicaltrials |
| NCT01285414 |
| Verubulin, Radiation Therapy, and Temozolomide to Treat Patients With Newly Diagnosed Glioblastoma Multiforme |
| completed |
| Phase 2 |
| 5 |
| Myrexis Inc.INDUSTRY |
| 1 |
| Apr 11, 2012 |
| clinicaltrials |
| NCT00777686 | Measuring Non-Enhancing Glioblastoma Progression | completed | — | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 30, 2012 | clinicaltrials |
| NCT00412542 | Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas | completed | Phase 2 | 78 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 28, 2012 | clinicaltrials |
| NCT01189513 | SCH-900105 in Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 20, 2012 | clinicaltrials |
| NCT00973557 | The Effect of Monoclonal Vascular Endothelial Growth Factor (VEGF) Antibody (Bevacizumab) on Pituitary Function | completed | — | 6 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 7, 2012 | clinicaltrials |
| NCT00071539 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | completed | Phase 2 | 56 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | Jan 20, 2012 | clinicaltrials |
| NCT00508456 | Dietary Methionine Restriction Plus Temozolomide for Recurrent GBM | terminated | Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 16, 2012 | clinicaltrials |
| NCT00504660 | 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients | completed | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 11, 2012 | clinicaltrials |
| NCT01105988 | Evaluating Tumor Pseudoprogression With FLT-PET and MRI | terminated | Early Phase 1 | 2 | Massachusetts General HospitalOTHER | 1 | Jan 6, 2012 | clinicaltrials |
| NCT01502241 | Phase III Trial of Primary Radio- or Chemotherapy in Malignant Astrocytoma of the Elderly(Methusalem) | completed | Phase 3 | 412 | Heidelberg UniversityOTHER | 2 | Dec 30, 2011 | clinicaltrials |
| NCT01441388 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | withdrawn | Phase 1 | 0 | PfizerINDUSTRY | 0 | Dec 20, 2011 | clinicaltrials |
| NCT00790452 | Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 8, 2011 | clinicaltrials |
| NCT00817284 | Bevacizumab and Irinotecan or Bevacizumab and Temozolomide With Concomitant Radiotherapy for Primary Glioblastoma Multiforme (GBM) | completed | Phase 2 | 60 | Ulrik LassenOTHER | 1 | Nov 30, 2011 | clinicaltrials |
| NCT00892931 | Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | Myrexis Inc.INDUSTRY | 1 | Oct 14, 2011 | clinicaltrials |
| NCT00515086 | Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 41 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 22, 2011 | clinicaltrials |
| NCT00715013 | Patupilone (EPO 906) in Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 9 | University of ZurichOTHER | 0 | Sep 15, 2011 | clinicaltrials |
| NCT00509301 | Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 | 12 | Peregrine PharmaceuticalsINDUSTRY | 1 | Aug 5, 2011 | clinicaltrials |
| NCT01124240 | Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene(ExCentric) | unknown | Phase 2 | 48 | Northern Sydney and Central Coast Area Health ServiceOTHER | 1 | Jul 26, 2011 | clinicaltrials |
| NCT00089427 | IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 24 | INSYS Therapeutics IncINDUSTRY | 1 | Jul 4, 2011 | clinicaltrials |
| NCT00024557 | Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients | completed | Phase 1 | 40 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00041587 | Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 80 | INSYS Therapeutics IncINDUSTRY | 3 | Jun 6, 2011 | clinicaltrials |
| NCT00064779 | Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | completed | Phase 1 | 18 | INSYS Therapeutics IncINDUSTRY | 1 | Jun 6, 2011 | clinicaltrials |
| NCT00076986 | The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme | completed | Phase 3 | 300 | INSYS Therapeutics IncINDUSTRY | 6 | Jun 6, 2011 | clinicaltrials |
| NCT00062504 | Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | terminated | Phase 2 | 30 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00104091 | Safety and Efficacy Study to Treat Recurrent Grade 4 Malignant Brain Tumors | completed | Phase 2 | 56 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00290771 | Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) | terminated | Phase 2 | 231 | NovartisINDUSTRY | 1 | May 16, 2011 | clinicaltrials |
| NCT00154375 | Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | completed | Phase 3 | 240 | Novartis PharmaceuticalsINDUSTRY | 1 | Apr 26, 2011 | clinicaltrials |
| NCT00686387 | Establishment of a Brain and Spinal Tumor Tissue Bank | unknown | — | 70 | Taipei Medical University WanFang HospitalOTHER | 1 | Apr 12, 2011 | clinicaltrials |
| NCT01181193 | Vitamin D for Treatment of Glioblastoma Multiforme | unknown | Phase 1 / Phase 2 | 20 | Soroka University Medical CenterOTHER | 1 | Mar 29, 2011 | clinicaltrials |
| NCT00635557 | Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme | unknown | Phase 1 / Phase 2 | 30 | Myrexis Inc.INDUSTRY | 1 | Mar 25, 2011 | clinicaltrials |
| NCT01317888 | Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas | unknown | N/A | 11 | Drexel UniversityOTHER | 0 | Mar 17, 2011 | clinicaltrials |
| NCT01308632 | Metronomic Temozolamide in Patients With Recurrent Glioblastoma | unknown | Phase 2 / Phase 3 | 30 | Grupo Español de Investigación en NeurooncologíaOTHER | 0 | Mar 4, 2011 | clinicaltrials |
| NCT00615186 | Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy(Glass-Art) | terminated | Phase 3 | 9 | Bradmer Pharmaceuticals Inc.INDUSTRY | 0 | Feb 10, 2011 | clinicaltrials |
| NCT00238797 | A Phase II Exploratory, Multicentre, Open-label, Non-comparative Study of ZD1839 (Iressa) and Radiotherapy in the Treatment of Patients With Glioblastoma Multiforme | completed | Phase 2 | 36 | AstraZenecaINDUSTRY | 1 | Jan 21, 2011 | clinicaltrials |
| NCT01242566 | Temozolomide in Elderly Patients With KPS < 70(TAG) | completed | Phase 2 | 70 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Nov 17, 2010 | clinicaltrials |
| NCT00562419 | CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan | unknown | Phase 2 | 72 | Adnexus, A Bristol-Myers Squibb R&D CompanyINDUSTRY | 1 | Oct 27, 2010 | clinicaltrials |
| NCT00768911 | CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme | unknown | Phase 1 | 30 | Adnexus, A Bristol-Myers Squibb R&D CompanyINDUSTRY | 1 | Oct 27, 2010 | clinicaltrials |
| NCT01208909 | Combined Approach to Resection of Glioblastoma (GBM) by 5-Aminolevulinic Acid (5-ALA) and Intraoperative Magnetic Resonance Imaging (MRI) | unknown | — | 40 | University of ZurichOTHER | 1 | Oct 22, 2010 | clinicaltrials |
| NCT00535379 | SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme(SURGE01-07) | unknown | Phase 2 | 70 | Medical University InnsbruckOTHER | 2 | Aug 30, 2010 | clinicaltrials |
| NCT00643825 | Prolonged Adjuvant Temozolomide vs "Stop & Go" in Glioblastoma Patients(PATSGO) | unknown | Phase 2 | 64 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Jul 23, 2010 | clinicaltrials |
| NCT00936052 | Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma(HBO) | unknown | Phase 2 | 20 | Neurological Surgery, P.C.OTHER | 1 | Jul 16, 2010 | clinicaltrials |
| NCT00800917 | A Study of Temsirolimus and Bevacizumab in Recurrent Glioblastoma Multiforme | completed | Phase 2 | 12 | Rigshospitalet, DenmarkOTHER | 1 | Jun 2, 2010 | clinicaltrials |
| NCT00165477 | Study of Lenalidomide and XRT in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 10, 2010 | clinicaltrials |
| NCT01083719 | A Comparison of FDG-PET Versus MRI Based Target Volume Delineation in Glioblastoma and the Role of FDG-PET/CT in the Alteration of MRI Based Target Volumes. | unknown | Phase 2 | 15 | Medanta Institute of Clinical ResearchOTHER | 0 | Mar 10, 2010 | clinicaltrials |
| NCT00243490 | Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors | withdrawn | Phase 2 | 5 | National Taiwan University HospitalOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00730262 | Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme | terminated | Phase 2 | 40 | Thallion PharmaceuticalsINDUSTRY | 2 | Dec 30, 2009 | clinicaltrials |
| NCT00503204 | Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour | completed | Phase 1 | 20 | AstraZenecaINDUSTRY | 2 | Nov 25, 2009 | clinicaltrials |
Data updated 23 days agoSource updated May 1, 2012source: clinicaltrials